HemaSphere (Jun 2022)
S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
- G. Garcia-Manero,
- E. S. Winer,
- D. J. DeAngelo,
- S. Tarantolo,
- D. A. Sallman,
- J. Dugan,
- S. Groepper,
- A. Giagounidis,
- K. Götze,
- K. H. Metzeler,
- C.-C. Li,
- L. Zhou,
- E. Martinez,
- M. Lane,
- R. von Roemeling,
- M. Bohme,
- A. S. Kubasch,
- A. Verma,
- U. Platzbecker
Affiliations
- G. Garcia-Manero
- 1 Luekemia, MD Anderson Cancer Center, Houston
- E. S. Winer
- 2 Dana-Faber Cancer Institute, Boston
- D. J. DeAngelo
- 2 Dana-Faber Cancer Institute, Boston
- S. Tarantolo
- 3 Nebraska Cancer Specialist, Omaha
- D. A. Sallman
- 4 Moffitt Cancer Center, Tampa
- J. Dugan
- 5 Novant Health Cancer Institute, Forsyth Medical Center, Winston-Salem, United States of America
- S. Groepper
- 6 Marien Hospital/ Univ. of Dusseldorf Germany, Dusseldorf
- A. Giagounidis
- 6 Marien Hospital/ Univ. of Dusseldorf Germany, Dusseldorf
- K. Götze
- 7 Faculty of Medicine Technical University of Munic, Munich
- K. H. Metzeler
- 8 Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany
- C.-C. Li
- 9 Curis, Lexington, United States of America
- L. Zhou
- 9 Curis, Lexington, United States of America
- E. Martinez
- 9 Curis, Lexington, United States of America
- M. Lane
- 9 Curis, Lexington, United States of America
- R. von Roemeling
- 9 Curis, Lexington, United States of America
- M. Bohme
- 9 Curis, Lexington, United States of America
- A. S. Kubasch
- 10 University Hospital Leipzig, Leipzig, Germany
- A. Verma
- 11 Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, United States of America
- U. Platzbecker
- 10 University Hospital Leipzig, Leipzig, Germany
- DOI
- https://doi.org/10.1097/01.HS9.0000843408.31385.3f
- Journal volume & issue
-
Vol. 6
pp. 30 – 31
Abstract
No abstracts available.